Csenge Advisory Group Has $563,000 Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Csenge Advisory Group lifted its stake in United Therapeutics Co. (NASDAQ:UTHRFree Report) by 21.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,767 shares of the biotechnology company’s stock after purchasing an additional 310 shares during the quarter. Csenge Advisory Group’s holdings in United Therapeutics were worth $563,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rise Advisors LLC purchased a new stake in United Therapeutics in the 1st quarter worth about $32,000. GAMMA Investing LLC purchased a new stake in United Therapeutics in the 4th quarter worth about $43,000. Benjamin F. Edwards & Company Inc. lifted its stake in United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares in the last quarter. Janiczek Wealth Management LLC lifted its stake in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 84 shares in the last quarter. Finally, Covestor Ltd lifted its stake in United Therapeutics by 83.1% in the 1st quarter. Covestor Ltd now owns 509 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 231 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on UTHR shares. UBS Group increased their price objective on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. Wells Fargo & Company raised their price target on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. Oppenheimer raised their price target on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $331.73.

Read Our Latest Stock Report on UTHR

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $338.61, for a total transaction of $1,218,996.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $44,019.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Friday, July 26th. The stock was sold at an average price of $338.61, for a total value of $1,218,996.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $44,019.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christopher Patusky sold 1,310 shares of United Therapeutics stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $264.35, for a total value of $346,298.50. The disclosure for this sale can be found here. Insiders sold 128,644 shares of company stock worth $39,863,643 in the last 90 days. 12.50% of the stock is owned by company insiders.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded up $8.81 during trading on Thursday, hitting $331.04. 333,837 shares of the stock were exchanged, compared to its average volume of 494,138. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $343.98. The company has a market capitalization of $14.73 billion, a price-to-earnings ratio of 15.65, a price-to-earnings-growth ratio of 1.17 and a beta of 0.55. The company’s fifty day simple moving average is $312.75 and its 200-day simple moving average is $263.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35.

United Therapeutics (NASDAQ:UTHRGet Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. During the same period in the previous year, the business posted $5.24 EPS. United Therapeutics’s revenue for the quarter was up 19.8% compared to the same quarter last year. Sell-side analysts expect that United Therapeutics Co. will post 24.79 EPS for the current fiscal year.

About United Therapeutics

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRFree Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.